Have a feature idea you'd love to see implemented?
Let us know!
LUNG Pulmonx Corp
Price (delayed)
$6.13
Market cap
$240.01M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.5
Enterprise value
$232.47M
Pulmonx Corporation is a commercial-stage medical technology company. The Company is focused on providing planning tools and treatments for obstructive lung disease. Its solutions include Zephyr Valve, Chartis Pulmonary Assessment
Highlights
The quick ratio is up by 30% since the previous quarter and by 4.2% year-on-year
Pulmonx's gross profit has increased by 27% YoY and by 4.7% from the previous quarter
Pulmonx's debt has increased by 38% QoQ and by 31% YoY
The company's equity fell by 24% YoY and by 8% QoQ
Key stats
What are the main financial stats of LUNG
Market
Valuations
Earnings
Shares outstanding
39.15M
Market cap
$240.01M
Enterprise value
$232.47M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.35
Price to sales (P/S)
3.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.04
Revenue
$76.58M
EBIT
-$53.71M
EBITDA
-$49.62M
Free cash flow
-$35.33M
Per share
Balance sheet
Liquidity
EPS
-$1.5
Free cash flow per share
-$0.91
Book value per share
$2.61
Revenue per share
$1.97
TBVPS
$4.37
Total assets
$172.63M
Total liabilities
$71.44M
Debt
$56.19M
Equity
$101.18M
Working capital
$129.86M
Debt to equity
0.56
Current ratio
8.97
Quick ratio
7.72
Net debt/EBITDA
0.15
Margins
Efficiency
Dividend
EBITDA margin
-64.8%
Gross margin
74.2%
Net margin
-75.6%
Operating margin
-77.4%
Return on assets
-33.1%
Return on equity
-50.8%
Return on invested capital
-45.1%
Return on capital employed
-34.4%
Return on sales
-70.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LUNG stock price
How has the Pulmonx stock price performed over time
Intraday
0%
1 week
-9.85%
1 month
-25.15%
1 year
-28.55%
YTD
-51.92%
QTD
-26.06%
Financial performance
How have Pulmonx's revenue and profit performed over time
Revenue
$76.58M
Gross profit
$56.81M
Operating income
-$59.25M
Net income
-$57.86M
Gross margin
74.2%
Net margin
-75.6%
Pulmonx's gross profit has increased by 27% YoY and by 4.7% from the previous quarter
The revenue has grown by 26% YoY and by 4.9% from the previous quarter
Pulmonx's net margin has increased by 24% YoY and by 6% QoQ
Pulmonx's operating margin has increased by 24% YoY and by 6% from the previous quarter
Growth
What is Pulmonx's growth rate over time
Valuation
What is Pulmonx stock price valuation
P/E
N/A
P/B
2.35
P/S
3.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.04
Pulmonx's EPS has increased by 7% YoY and by 2.6% from the previous quarter
The P/B is 27% lower than the last 4 quarters average of 3.2
The company's equity fell by 24% YoY and by 8% QoQ
The price to sales (P/S) is 41% less than the last 4 quarters average of 5.3
The revenue has grown by 26% YoY and by 4.9% from the previous quarter
Efficiency
How efficient is Pulmonx business performance
Pulmonx's ROS has increased by 27% YoY and by 6% from the previous quarter
The company's return on equity fell by 25% YoY and by 6% QoQ
LUNG's return on invested capital is up by 20% year-on-year and by 9% since the previous quarter
The ROA fell by 8% YoY
Dividends
What is LUNG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LUNG.
Financial health
How did Pulmonx financials performed over time
Pulmonx's total assets is 142% more than its total liabilities
Pulmonx's total liabilities has increased by 32% from the previous quarter and by 21% YoY
The quick ratio is up by 30% since the previous quarter and by 4.2% year-on-year
Pulmonx's debt is 44% lower than its equity
The debt to equity has surged by 75% year-on-year and by 51% since the previous quarter
Pulmonx's debt has increased by 38% QoQ and by 31% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.